Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Repurchased (2019 - 2025)

Historic Shares Repurchased for C4 Therapeutics (CCCC) over the last 5 years, with Q3 2025 value amounting to $24000.0.

  • C4 Therapeutics' Shares Repurchased fell 7176.47% to $24000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $179000.0, marking a year-over-year decrease of 773.2%. This contributed to the annual value of $194000.0 for FY2024, which is 7636.36% up from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Shares Repurchased is $24000.0, which was down 7176.47% from $155000.0 recorded in Q1 2025.
  • Over the past 5 years, C4 Therapeutics' Shares Repurchased peaked at $155000.0 during Q1 2025, and registered a low of $16000.0 during Q3 2023.
  • In the last 3 years, C4 Therapeutics' Shares Repurchased had a median value of $89500.0 in 2023 and averaged $80500.0.
  • As far as peak fluctuations go, C4 Therapeutics' Shares Repurchased surged by 43125.0% in 2024, and later plummeted by 7176.47% in 2025.
  • C4 Therapeutics' Shares Repurchased (Quarter) stood at $16000.0 in 2023, then surged by 431.25% to $85000.0 in 2024, then crashed by 71.76% to $24000.0 in 2025.
  • Its Shares Repurchased stands at $24000.0 for Q3 2025, versus $155000.0 for Q1 2025 and $85000.0 for Q3 2024.